Authors: Faezeh Koohestani*, Wenan Qiang, Takeshi Kurita, Maureen Getty, Jacob Schanks, Amy MacNeill, and Romana Nowak
Uterine leiomyomas are the most prevalent benign tumors of the reproductive tract in women. Available treatments for leiomyomas are limited to surgical procedures or hormonal therapy, which are costly and have significant side effects. In an effort to develop alternative therapeutic strategies, we tested the drug halofuginone (HF) in primary leiomyoma smooth muscle cells (LSMCs) in vitro and in vivo. Our results show that treatment of LSMCs with 50nM HF in vitro caused a significant decrease in cell proliferation and expression of collagens, which are hallmarks of these tumors. These effects were also found to be mediated through the MAPK and SRC pathways. We next tested the inhibitory effects of HF in an in vivo leiomyoma-xenografted mouse model. Treatment of mice with 0.25 mg/kg/day HF for four weeks significantly reduced the size of tumors by 50% with no effect on body weight or overall health of the animals. HF also caused a decrease in cell proliferation and increased in apoptosis. Our findings demonstrate that the antifibrotic drug HF inhibits the growth of leiomyomas through its effects on major cell signaling pathways, and may lead to the development of HF as an efficient therapeutic strategy for treatment of these common tumors.
Good morning, everyone. Thank you for attending this session to listen to my talk. I also would like to thank the Organizing Committee for
Didn't I turn it on? Sorry.
For giving me the opportunity to present my research on the effects of halofuginone on uterine leiomyoma cells.
Uterine leiomyomas, which are also known as
fibroids, are
myomas, are known as the most common
gynecologic tumors in women during their reproductive years.
The overall incidence of these tumors in
Caucasian women is as high as 60% and 80% in African-American women.
Although these tumors are benign in nature, they can cause severe symptoms in women such as abnormal uterine bleeding, leading to anemia,
reproductive dysfunctions such as infertility,
recurrent abortion, and also preterm labor.
They also are associated with high pelvic pain and pressure.
These symptoms have been
the lead cause of
hysterectomies in the United States, and it's been
mentioned that about 600 hysterectomies are performed annually in the U.S. for the management of these
tumors. And the overall cost of these
tumors with regard to indirect and direct cost
is estimated to be in between three to six billion dollars annually in the United States.
These tumors, which arise from the uterine smooth muscle cells of the uterus,
can form in different locations within the uterine cavity, so hence we have substeroidal, intramural,
pedunculated, or the submucosal
formation of these tumors.
A patient can have as low as one
tumor in the uterine cavity to as high as four or five, and they can vary in size from a few millimeters to a few
centimeters. At the cellular level, these tumors are characterized by two main features.
The first one is an increased rate of proliferation compared to the normal
myometrial tissue, as you can see here in this PCNN, standing between the two
disease and normal tissue. The second feature of these tumors, which is actually the hallmark of them, are an increased
synthesis and deposition of extracellular matrix, mainly collagens one and three. Here in this mason's trichrome staining,
which stains collagens in blue,
you can appreciate the abundance presence of collagens in the leiomyoma tissue as compared to the adjacent myometrium tissue. In addition to that,
electromicroscopic analysis have
shown that the outer structure of these collagens in leiomyoma tissue is
completely distorted in that they have lost the completely packed, organized
formation here to these random formations, which are not indicative of a healthy extracellular matrix.
Unfortunately, despite the prevalence of these tumors, their etiology is not fully known.
There are, however, several suggested theories based on the research that has been done so far. One of those suggests
on genetic, epigenetic, and also changes in the
RNAi machinery as being the
underlying cause of these tumors. The other one is based on clinical and also in vitro studies,
showing that there are changes in the expression of
sex historic hormones,
estrogen and progesterone specifically, and their associated receptors. There are also reports on an increase
in specific growth factors like PGF-beta and PDGF receptor, which is not known whether these are the primary or the secondary
effectors of these tumors.
In addition to that, epidemiological studies have indicated
environmental and predisposing risk factors such as smoking,
use of birth controls,
high BMI, low vitamin deficiency as having a role in the pathogenesis of these tumors.
Based on the knowledge that we have so far,
there has been a few
treatments available for women, which I can categorize them into three major ones. One is surgical, the other one is
therapeutic, and lastly the non-invasive
treatments that are available.
Starting with surgical ones, which is the main form of intervention for these treatments,
we have two forms of surgeries. One is myomectomy and the other one is hysterectomy. Hysterectomy is the gold standard
treatment for these tumors, which of course takes care of the problem
totally by removing the uterus.
Myomectomy leads that by just removing the
tumor from the
uterus.
Although they provide
complete relief of the symptom for the patient, they are associated with high costs and complications after the surgery.
After surgical
interventions, most patients are placed on
therapeutic treatments, mainly hormone
treatments such as GnRH and
agonists and
anti-estrogen and progesterone treatments. There are also some cases where
inhibitors for enzymes involved in the hormone production is also
prescribed to these patients.
These again would only take care of the symptoms on a temporary basis because once the patient stops taking these, the tumor growth comes back and
so forth, the symptoms.
In recent years, the non-invasive approaches have gained momentum.
Some of these include high-frequency
ultrasonography and arterial embolization.
Although they seem to be less invasive and so far have shown some
lesser side effects, they are not complete studies showing their efficacy and they may not be suitable for all women.
So,
overall, I should say that although there are so many options available for these women,
they do not address the underlying cause of these diseases. They only relieve the symptoms and secondly, they
have side effects and finally, they are not suitable for women who would like to maintain their fertility.
So, there is therefore the need for development of alternative therapeutic treatments for these
patients.
In order to address this need, we
decided to look at basic features of these tumors, which was, as I mentioned, increased rate of proliferation and
collagen expression. We thought whether we should try
targeting the increased expression of collagens as a form of therapeutic treatment.
In doing that, we looked at similar fibrotic diseases and found that there are four major drugs that are currently being studied
to control fibrosis. These are interferons, pyrphenidone,
trichostatin A, and halofuginil. Out of these four major drugs,
halofuginil seemed to be the one that's specifically targeting collagen expression. This
drug is a plant alkaloid derived from the
plant Dichlorofibrifugin. It's been used for thousands of years in Chinese medicine
to control fever and malaria.
In Western countries, it's been used as a cocciduestat in poultry industry, and it was just a
overdose of this drug in a poultry industry in Israel in the early 90s, which revealed that this drug specifically targets expression of collagens.
Currently, there are clinical studies
using this drug for
fibrotic diseases such as scleroderma and respinosus, also muscular dystrophy, and more recently
for controlling
cancer metastasis as well.
So based on these data, we thought why don't we try
testing the inhibitory effects of halofuginil in uterine leiomyomas. In doing that, we
decided to look both at in vitro and in vivo models using primary cells obtained from women who were going through a
surgical intervention.
After doing those responses studies and finding the right concentration of halofuginil to be used for our in vitro studies,
we first looked at the effect of halofuginil on proliferation of leiomyomas, smooth muscle cells.
Here you see results using thymidine incorporation assay where we had cells
cultured in vitro in the absence or presence of PDGF, which is one of the major growth factors involved in the pathogenesis of this disease.
Cells were either treated with just halofuginil for 24 hours or
treated with both halofuginil and PDGF for 24 hours.
And as you can see, this treatment was very effective in reducing the proliferation of leiomyoma cells.
We next wanted to see whether
halofuginil had any carryover effects once it was removed from the media. And the results show that yes, it does, although
the proliferation goes back higher than what we saw before, but it's still significantly less than what we see without
halofuginil treatment.
Our next question was whether halofuginil could target the expression of collagen as has been seen in similar
fibrotic diseases.
So we did a time-course study with 15 nanomolar halofuginil and found that that halofuginil could very efficiently
downregulate the expression of both collagens 1 and 3 in leiomyoma smooth muscle cells.
In order to see how these inhibitory effects are occurring, we looked at any alterations
done by halofuginil on major signaling pathways involved in proliferation and collagen synthesis. These were MAC kinase, SARK, and AKT pathways.
Treatment with a 15 nanomolar halofuginil showed that there was no change at the activation of AKT pathway.
However, both ERK and SARK kinase were
activated by halofuginil in as early as 15 minutes.
We next
pre-treated these cells with halofuginil for six hours and then stimulated them with PDGF to see whether halofuginil could alter the activation of
SARK and MAC kinase signaling pathways that has been known to be done by a PDGF treatment.
The results showed that, yes, it does. It decreases the activation of ERK and SARK
downstream of PDGF receptor because we didn't see any change at the level of the receptor. To see whether we could replicate these in vitro
results in an in vivo setting, we developed an in vivo
mouse model in collaboration with doctors Kurita and Chiang at Northwestern University. Here, we have used
adult female over-decomized in immune-deficient mice placed on hormone regimen, and then we transplanted
primary cells from patient under the kidney capsule of these mice. After the establishment of tumor for four weeks,
animals were placed in, were grouped in two, and one received vehicle and the other one halofuginil on two different doses.
Here, you can see the presence of tumor under the kidney capsule of vehicle-treated animals and also halofuginil-treated ones.
And here is an HNA staining of
primary cells xenografted next to the kidney of
mouse.
We started with 500 micrograms per kilogram body weight treatment of these mice for five days a week for the duration of four weeks.
Here, you see that the tumor volume was significantly reduced by about 35%
in halofuginil-treated animals. These are data from six vehicle animals and eight halofuginil treatments.
Although the results looked very promising,
these treatments seemed to be
not safe for mice hosts. We ended up losing a lot of mice during the
course of the treatment, and this was quite obvious by looking at their body weight.
So, we changed the treatment to every other day. Here, it looked like
the treatment was better tolerated by mice as we did not end up,
we didn't have as many dead mice on our hands, and there was still differences between the body weight,
but not as much as the previous treatment.
Interestingly, there was not much of a significant difference between the reduction of tumor volume that was seen with the daily treatment.
Based on these data, we decided to cut back on the dose of the halofuginil to see whether we would take care of the health
of the animals while
shrinking the size of these tumors. So, we went with 250 micrograms per kilogram halofuginil. Again, given to animals
intraperitoneally for
five days a week for four weeks. Here, mice tolerated this dose very well.
We didn't see any effect on the body weight of these animals. We further analyzed major organs of these mice.
In both vehicle and halofuginil treatments, these body organs were heart, lung, liver,
kidney, bladder, vagina, and finally, uterus. Again, we didn't see any
side effect on any of these major organs,
so indicating that this dose and this treatment regimen seemed to be safe for our mice hosts.
And of course, our question was, does this dose affect the size of these tumors? Yes, it did. It decreased that significantly
in halofugin treated animals, looking at
six
mice for which had received
tumors from four patients.
In order to see how this inhibitory effect
is happening,
we looked at proliferation of xenografted tumors. Using Ki-67 staining,
we noticed that the rate of proliferation was significantly reduced in halofugin treated versus vehicle treated animals.
This seemed to be occurring at the same time with an induction of apoptosis in halofugin treated animals as observed here by
tunnel staining.
So, so far,
our in vitro studies have shown that halofugin is very efficient in
inhibiting the proliferation of lyoma in my smooth muscle cells, as well as
inhibiting the expressions of collagens 1 and 3, and it seems to be exerting these inhibitory effects through
modulations of MAP kinase and SAR kinase signaling pathways.
Our work with the in vivo mouse model has shown that
these
results could be replicated in an in vivo system through our regulation of apoptosis and
down regulation of
proliferation, and we think that this mouse model can serve as a very good model for
testing
halofugin as a therapeutic treatment in our clinical studies. As for our future plans,
we are going to look at the expression of collagens in our in vivo model to see whether
similar results would be observed in the in vivo system. We are now in the process of
looking at the mRNA expression of major fibrotic factors like
1 and 3 collagens, also the cross-linking enzyme for collagens lifestyle oxidase in both in vivo and in vitro.
We are planning to treat these animals for a longer period of time,
which will be eight weeks, to see whether we will see less reduction of tumor volume upon halofugin on treatment.
Finally, we would like to have the treatment scheme where we would remove halofugin to see how long the carryover effects of these
halofugin inhibitor effects would last.
With that, I would like to thank my advisor, Dr. Romana Novak, for her ongoing support. Also our collaborators,
Drs. Kurita, Keong, and McNeil.
I would like to specifically thank patients and Barbara Hall, the research coordinator at Card Hospital,
who has done a great job in collecting samples for us.
We have also received some samples from Northwestern Feinberg School of Medicine. I would like to thank
members of my committee, Drs. Barb, Eunice, Floss, Kim, and Miller for their ongoing
suggestions and advice, and also wonderful
people at Novak Lab, and of course funding by NIH. With that, I would be glad to take any questions you may have.
Is there any interest in perhaps obtaining a more open derivative of halofugin, or are you going more in the direction of coupling it to another halofugin?
That's a very good direction for future.
We have that in mind, but we would like to further investigate this as we do with this molecule as is.
But in future, we would definitely like to fine-tune, depending on the results we see,
specifically with potential side effects.
So far, we have only had treatments for four weeks.
That's why we are going for eight weeks to see if there is a time-dependent factor going on.